In lung cancer, EpCAM has been found to be a downstream target of metastasis-associated protein 1 (MTA1), and MTA1 overexpression can increase EpCAM levels and enhance tumor metastasis, leading to poor prognosis (32). Here, EPCAM is linked to lung carcinoma.